The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer.
暂无分享,去创建一个
Qianlan Yao | Wentao Yang | Wei-Wei Jiang | Huijuan Yang | Yutuan Wu | L. Xiang | Wanling Shi | Xueyan Ouyang | Zha Ji | Yi Wang | L. Xiang
[1] S. Vaseghi,et al. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines , 2021, Molecular Biology Reports.
[2] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[3] S. Wiemann,et al. Abrogating GPT2 in triple‐negative breast cancer inhibits tumor growth and promotes autophagy , 2020, International journal of cancer.
[4] Yiqing Zhao,et al. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers , 2020, Cancer Research.
[5] Ning Wang,et al. Glutamic-Pyruvic Transaminase 1 Facilitates Alternative Fuels for Hepatocellular Carcinoma Growth—A Small Molecule Inhibitor, Berberine , 2020, Cancers.
[6] K. Tew,et al. Oxidative Stress in Cancer. , 2020, Cancer cell.
[7] J. Waldron,et al. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. , 2020, Oral oncology.
[8] A. Mai,et al. Sirt4: A Multifaceted Enzyme at the Crossroads of Mitochondrial Metabolism and Cancer , 2020, Frontiers in Oncology.
[9] N. Lee,et al. A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. , 2020, International journal of radiation oncology, biology, physics.
[10] G. Ke,et al. Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA-E545K Mutation , 2019, Molecular Cancer Therapeutics.
[11] M. Najafi,et al. Targets for improving tumor response to radiotherapy. , 2019, International immunopharmacology.
[12] K. Machado,et al. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Yanni Peng,et al. Glutamine Synthetase Promotes Radiation Resistance via Facilitating Nucleotide Metabolism and Subsequent DNA Damage Repair. , 2019, Cell reports.
[14] P. Gestraud,et al. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome , 2019, EBioMedicine.
[15] Y. See,et al. Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1) , 2019, Cellular and Molecular Neurobiology.
[16] D. Rubinsztein,et al. Leucine Signals to mTORC1 via Its Metabolite Acetyl-Coenzyme A , 2019, Cell metabolism.
[17] Wei-Wei Jiang,et al. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer , 2018, Journal of Hematology & Oncology.
[18] W. Koom,et al. Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. , 2018, Gynecologic oncology.
[19] Dejan Juric,et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Ahmad,et al. The Role of Sirtuins in Antioxidant and Redox Signaling. , 2017, Antioxidants & redox signaling.
[21] Changhao Chen,et al. HIF‐2α regulates non‐canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma , 2017, Journal of cellular and molecular medicine.
[22] K. Kinzler,et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer , 2016, Nature Communications.
[23] C. Ferreira,et al. A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I , 2016, Cancer Chemotherapy and Pharmacology.
[24] J. Pignon,et al. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] H. Liao,et al. RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint. , 2014, Anticancer Research.
[26] D. Erdmann,et al. Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials , 2014, Molecular Cancer Therapeutics.
[27] Jie Zhou,et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. , 2013, Biochimica et biophysica acta.
[28] K. Harrington,et al. The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[29] Gregory Stephanopoulos,et al. The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4 , 2013, Cell.
[30] Xiaoling Xu,et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. , 2013, Cancer cell.
[31] J. Maris,et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. , 2012, Cancer cell.
[32] H. Aburatani,et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. , 2012, Cancer cell.
[33] T. Pandita,et al. The Proteasome Activator PA200 Regulates Tumor Cell Responsiveness to Glutamine and Resistance to Ionizing Radiation , 2012, Molecular Cancer Research.
[34] W. Wheaton,et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.
[35] I. Cotgreave,et al. Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma. , 2009, International journal of molecular medicine.
[36] Jennifer E. Van Eyk,et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2016 .
[37] N. Hay,et al. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.
[38] S. Weitzman,et al. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc , 2008, Oncogene.
[39] Ching-Chow Chen,et al. Akt Phosphorylation of p300 at Ser-1834 Is Essential for Its Histone Acetyltransferase and Transcriptional Activity , 2005, Molecular and Cellular Biology.
[40] J. Chen,et al. Role of Akt/protein kinase B in the activity of transcriptional coactivator p300 , 2004, Cellular and Molecular Life Sciences CMLS.
[41] R. Goodman,et al. CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.